Influence of Human Paraoxonase-1 Polymorphism (Q192R) on Serum Levels of Clinical Biomarkers Indicatives of Cardiovascul
- PDF / 761,477 Bytes
- 20 Pages / 439.37 x 666.142 pts Page_size
- 71 Downloads / 189 Views
Influence of Human Paraoxonase‑1 Polymorphism (Q192R) on Serum Levels of Clinical Biomarkers Indicatives of Cardiovascular Diseases Risk in Mexican Women Ángeles C. Ochoa‑Martínez1,2 · Sandra T. Orta‑García1,2 · José A. Varela‑Silva1,2,3 · Iván N. Pérez‑Maldonado1,2,4 Received: 24 September 2019 / Accepted: 30 May 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Human paraoxonase-1 (PON1) is a hydrolytic enzyme related in the onset, establishment, and progression of inflammatory illnesses, including cardiovascular diseases (CVD). Therefore, the primary goal of this investigation was to determinate the influence of the PON1 gene polymorphism (Q192R) on prognostic biomarkers of CVD in women (n = 350) from San Luis Potosi, Mexico. For everyone enrolled, anthropometric, clinical, and biochemical measurements were acquired. Q192R polymorphism of the PON1 gene was assessed by real-time PCR using TaqMan probes. Also, quantification and/or calculation of suggested predictive CVD biomarkers were completed. The association between PON1(Q192R) polymorphism with clinical predictive CVD biomarkers was assessed using univariate and multivariate logistic regression models. Genotype PON1 (Q192R) frequencies were: 18%, 47% and 35% for QQ, QR, and RR, respectively. Besides, the frequency of the variant R allele was 0.58. Furthermore, robust significant associations were found between PON1 (Q192R) polymorphism with serum ADMA [OR (95% CI); 3.50 (1.20–5.00), p 0.05
Waist circumference (cm)
90.0 ± 8.00
90.5 ± 3.50
94.5 ± 5.00
> 0.05
Hip circumference (cm)
103 ± 15.0
107 ± 12.0
105 ± 10.0
> 0.05
Waist/hip ratio
0.88 ± 0.10
0.87 ± 0.05
0.89 ± 0.07
> 0.05 0.01
Systolic blood pressure (mm Hg)
117 ± 8.00
115 ± 6.00
129 ± 10.0*
Diastolic blood pressure (mm Hg)
68.0 ± 5.00
69.0 ± 8.00
78.0 ± 15.5*
25.5 ± 5.00
27.5 ± 7.50
29.0 ± 3.50
> 0.05
Body fat (%)
39.0 ± 5.50
36.0 ± 7.50
37.5 ± 7.00
> 0.05
Visceral fat (%)
8.00 ± 3.50
9.00 ± 4.00
8.50 ± 2.50
0.60
Body mass index (kg/m2)
0.03
Bold values indicate statistically significant *Significantly different compared to QQ group and QR group
and DBP were significantly different (p 0.05
VLDL-C (mg/dL) non-HDL-C (mg/dL)
14.0 ± 5.00
12.5 ± 3.50
15.5 ± 3.00
> 0.05
138.0 ± 12.0
147.0 ± 10.0
146.0 ± 13.5
> 0.05
Bold value indicates statistically significant HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C verylow-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol *Significantly different compared to QQ group and QR group Table 4 Atherogenic indices of evaluated women according to PON1 (Q192R) genotype
Variable/genotype QQ
QR
RR
n
153
114
58
FRS (% risk)
7.50 ± 1.50 9.90 ± 3.00 11.0 ± 6.00*
CRI
3.95 ± 0.75 3.80 ± 0.80 4.25 ± 1.25
p 0.03
> 0.05 0.01
LAP
67.5 ± 12.5 68.0 ± 10.0
AIP
0.13 ± 0.05 0.17 ± 0.09 0.22 ± 0.07*
89 ± 5.00*
AC
2.80 ± 1.05 2.75 ± 0.55 2.75 ± 1.15
> 0.05
CRR 1
3.50 ± 1.05 3.75 ± 1.30 3.90 ± 1.10
> 0.0
Data Loading...
